<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138498</url>
  </required_header>
  <id_info>
    <org_study_id>CTx-1301-001</org_study_id>
    <nct_id>NCT04138498</nct_id>
  </id_info>
  <brief_title>CTx-1301 Comparative Bioavailability Study</brief_title>
  <official_title>A Randomized, Single-dose, Four-sequence, Four-period, Crossover Study in Adult ADHD Subjects to Establish Safety, Tolerability, and Comparative Bioavailability of CTx-1301 (Dexmethylphenidate) to Focalin XR™ Under Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cingulate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cingulate Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the bioavailability of CTx-1301&#xD;
      (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose&#xD;
      proportionality of CTx-1301. In addition, this study seeks to characterize the&#xD;
      pharmacokinetics of dexmethylphenidate and evaluate the safety and tolerability of CTx-1301.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will comprise of a randomized, single-dose, four-sequence, four-period, in-clinic&#xD;
      crossover study in approximately 36 adult ADHD subjects. All subjects considered eligible at&#xD;
      Screening will proceed to tolerability test day, dosing 40 mg Focalin XR to evaluate safety&#xD;
      and tolerability of the higher dose of d-MPH. If subject is able to safely tolerate the test&#xD;
      dose, and meets all inclusion/exclusion criteria, they will be considered eligible for&#xD;
      randomization into the study. All subjects will be randomized to receive four treatments&#xD;
      throughout the course of the study; one CTx-1301 trimodal d-MPH tablet containing 6.25 mg&#xD;
      d-MPH, one Focalin 5 mg XR capsule, one CTx-1301 50 mg tablet, and one 40 mg Focalin XR&#xD;
      capsule. Administration of study drug will occur only on Assessment Days; no study drug will&#xD;
      be administered during screening or unscheduled days (USVs).&#xD;
&#xD;
      The lowest and highest doses of CTx-1301 (dexmethylphenidate, 6.25 and 50 mg) were selected&#xD;
      to bridge to the lowest and highest doses of Focalin XR (dexmethylphenidate, 5 and 40 mg) in&#xD;
      this comparative BA study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>d-MPH Plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-infinity)</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>Area under the curve from time 0 extrapolated to infinite time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(Last)</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>AUC from time 0 to the last measurable concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial AUCs</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>Rate at which a drug is removed from the system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>Time (Hours) after administration of a drug when the maximum plasma concentration is reached</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlag</measure>
    <time_frame>Hours 0 to 28</time_frame>
    <description>Delay (hours) between the time of dosing and time of appearance of concentration in the sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Day 0 to Day 10</time_frame>
    <description>TEAEs will be measured from Day 0 to Day 10 (End of Study)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (ADBC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (BACD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 (CBDA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 (DCAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmethylphenidate 5 Mg Oral Capsule, Extended Release</intervention_name>
    <description>Reference listed drug (RLD) for comparative BA evaluation</description>
    <arm_group_label>Sequence 1 (ADBC)</arm_group_label>
    <arm_group_label>Sequence 2 (BACD)</arm_group_label>
    <arm_group_label>Sequence 3 (CBDA)</arm_group_label>
    <arm_group_label>Sequence 4 (DCAB)</arm_group_label>
    <other_name>Focalin XR (dexmethylphenidate) 5 mg Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmethylphenidate 6.25 mg Tablet</intervention_name>
    <description>Experimental drug for comparative BA evaluation</description>
    <arm_group_label>Sequence 1 (ADBC)</arm_group_label>
    <arm_group_label>Sequence 2 (BACD)</arm_group_label>
    <arm_group_label>Sequence 3 (CBDA)</arm_group_label>
    <arm_group_label>Sequence 4 (DCAB)</arm_group_label>
    <other_name>CTx-1301 (dexmethylphenidate) 6.25 mg Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmethylphenidate 40 Mg Oral Capsule, Extended Release</intervention_name>
    <description>Reference listed drug (RLD) for comparative BA evaluation</description>
    <arm_group_label>Sequence 1 (ADBC)</arm_group_label>
    <arm_group_label>Sequence 2 (BACD)</arm_group_label>
    <arm_group_label>Sequence 3 (CBDA)</arm_group_label>
    <arm_group_label>Sequence 4 (DCAB)</arm_group_label>
    <other_name>Focalin XR (dexmethylphenidate) 40 mg capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmethylphenidate 50 mg Tablet</intervention_name>
    <description>Experimental drug for comparative BA evaluation</description>
    <arm_group_label>Sequence 1 (ADBC)</arm_group_label>
    <arm_group_label>Sequence 2 (BACD)</arm_group_label>
    <arm_group_label>Sequence 3 (CBDA)</arm_group_label>
    <arm_group_label>Sequence 4 (DCAB)</arm_group_label>
    <other_name>CTx-1301 (dexmethylphenidate) 50 mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gender&#xD;
&#xD;
             a. Male or Female&#xD;
&#xD;
          2. Age&#xD;
&#xD;
             a. Aged between 18 and 55 years inclusive.&#xD;
&#xD;
          3. Weight and BMI&#xD;
&#xD;
               1. Body weight ≥ 50 kg&#xD;
&#xD;
               2. BMI ≥ 18 and ≤ 35&#xD;
&#xD;
          4. Compliance&#xD;
&#xD;
               1. Understands and is willing, able and likely to comply with all study procedures&#xD;
                  and restrictions.&#xD;
&#xD;
               2. If sexually active, male subjects must use the double-barrier method (condom and&#xD;
                  spermicide) for birth control during the study and for 90 days following the last&#xD;
                  administration of study drug.&#xD;
&#xD;
               3. If sexually active, female subjects of child-bearing potential must use an&#xD;
                  acceptable method of contraception, including abstinence from heterosexual&#xD;
                  intercourse, hormonal contraceptives, intrauterine device (IUD) with or without&#xD;
                  hormones, or double-barrier method (e.g. condom and spermicide), during the study&#xD;
                  and for 30 days following the last administration of study drug.&#xD;
&#xD;
               4. Male subjects must agree not to donate sperm during the study and for 90 days&#xD;
                  following the last administration of study drug.&#xD;
&#xD;
               5. Female subjects must agree not to donate eggs during the study and for 30 days&#xD;
                  following the last administration of study drug.&#xD;
&#xD;
          5. Consent a. Demonstrates understanding of the study and willingness to participate as&#xD;
             evidenced by voluntary written informed consent (signed and dated) obtained before any&#xD;
             study-related activities are performed.&#xD;
&#xD;
          6. Indication&#xD;
&#xD;
               1. Subject must report history of diagnosis of ADHD.&#xD;
&#xD;
               2. If subject is currently taking stimulant medication, they must be willing and&#xD;
                  able to safely abstain from any other ADHD treatment during 96 hrs. prior to&#xD;
                  check-in on Day -4 and through the complete duration of the study.&#xD;
&#xD;
          7. General Health&#xD;
&#xD;
               1. Good general health (in the opinion of an investigator) with no clinically&#xD;
                  significant or relevant abnormalities on medical history or physical examination&#xD;
                  which could affect the safety of the subject or study data.&#xD;
&#xD;
               2. No vomiting or fever within 24-hours of check-in at Day -4&#xD;
&#xD;
               3. Subject has sufficient venous access to allow cannulation and/or venipuncture to&#xD;
                  obtain the required volume of blood for this study.&#xD;
&#xD;
               4. Subject must currently be taking or previously have taken a stimulant medication&#xD;
                  for ADHD.&#xD;
&#xD;
          8. Smoking/Caffeine/Alcohol&#xD;
&#xD;
               1. Subject must be able to refrain from smoking cigarettes 1 hour prior to dosing&#xD;
                  and 7 hours after dosing on dosing days. Subject must agree not to smoke more&#xD;
                  than one cigarette per hour, not to exceed 10 cigarettes per day.&#xD;
&#xD;
               2. Subject must be able to refrain from caffeine for 10 hours prior to check-in at&#xD;
                  Day -4 and for the duration of the study.&#xD;
&#xD;
               3. Subject must be able to refrain from using alcohol 48 hrs. prior to Day -4 and&#xD;
                  for the duration of the study.&#xD;
&#xD;
          9. ADHD Medication History&#xD;
&#xD;
               1. Subject's medication history suggests they will be able to tolerate a 40 mg dose&#xD;
                  of dexmethylphenidate.&#xD;
&#xD;
               2. Subject must demonstrate tolerability of dexmethylphenidate assessed by&#xD;
                  tolerability day/test dose of 40 mg Focalin XR as evaluated by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical History&#xD;
&#xD;
               1. Current and/or recurrent disease or illness that, in the opinion of an&#xD;
                  investigator, could affect the study conduct, study outcome, subject safety, or&#xD;
                  pharmacokinetic (PK) assessments (e.g., hepatic disorders, renal insufficiency,&#xD;
                  non-self-limiting gastrointestinal disorders, congestive heart failure).&#xD;
&#xD;
               2. Current and/or previous history of any other serious, severe or unstable&#xD;
                  psychiatric illness which in the opinion of the investigator, may require&#xD;
                  treatment (e.g. anxiety, psychosis, mood disorder, motor tics or suicidality) or&#xD;
                  make the subject unlikely to fully complete the study, and/or any condition that&#xD;
                  presents undue risk from the study medication or procedures.&#xD;
&#xD;
               3. Subject cannot have suicidal thoughts within the last 6 months as supported by&#xD;
                  the Columbia Suicide Severity Rating Scale (C-SSRS).&#xD;
&#xD;
               4. Positive test results for Human Immunodeficiency Virus (HIV)-1/HIV-2 antibodies,&#xD;
                  Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibody (HCVAb).&#xD;
&#xD;
               5. A family history of sudden cardiac or unexplained death.&#xD;
&#xD;
               6. Any condition or abnormal laboratory finding that could result in harm to the&#xD;
                  subject, affect the outcome of the study, or suggest unstable medical illness.&#xD;
&#xD;
               7. As a result of the MINI, medical history, physical examination, and/or screening&#xD;
                  investigations (including ECG results, vital signs and/or laboratory&#xD;
                  abnormality), an Investigator considers the subject disqualified for the study.&#xD;
&#xD;
               8. Subject plans to undergo elective procedures/surgery at any time during the&#xD;
                  study.&#xD;
&#xD;
               9. Subject has had surgery within the past 90 days.&#xD;
&#xD;
              10. Subject of child-bearing potential is pregnant or planning to become pregnant&#xD;
                  during the duration of the study or within 30 days of the end of the study.&#xD;
&#xD;
              11. Subject is breast-feeding during the study or within 30 days of the study.&#xD;
&#xD;
          2. Medications&#xD;
&#xD;
             a. Subject has taken any medication that, in the opinion of an Investigator, has been&#xD;
             shown to alter the PK of d-MPH.&#xD;
&#xD;
             b. Use of any prescription medication within 14 days prior to Day -3 (ADHD medications&#xD;
             must be discontinued at least 96 hours prior to check-in at Day -4), and/or use of any&#xD;
             OTC medications (such as antacids, vitamins, minerals, dietary/herbal preparations,&#xD;
             and nutritional supplements) within 7 days prior to Day -3 unless jointly approved by&#xD;
             an Investigator and Sponsor.&#xD;
&#xD;
             i. Subjects are permitted to take hormonal contraceptives and hormone replacement&#xD;
             therapy at acceptable levels if stable at least 30 days prior to Day -4, through the&#xD;
             duration of the study, and for 30 days after the study ends.&#xD;
&#xD;
             ii. Acetaminophen (up to 2 grams per day) may be used during the study under the&#xD;
             direction of the Investigator.&#xD;
&#xD;
             iii. On a case-by-case basis, an Investigator is permitted to allow the use of certain&#xD;
             concomitant medications, for example, to treat an AE, as long as an Investigator&#xD;
             determines that the medication will not affect the subject's safety or study integrity&#xD;
             (eg, topical medications).&#xD;
&#xD;
          3. Alcohol/Substance Abuse&#xD;
&#xD;
               1. Recent history (within the last year) of alcohol or other substance abuse.&#xD;
&#xD;
               2. Subject has positive breath alcohol test or urine test for drugs of abuse at&#xD;
                  screening or check-in (prescribed ADHD medication is acceptable during screening&#xD;
                  but must be stopped at least 96 hrs prior to check in at Day -4). Note: At the&#xD;
                  discretion of an Investigator, the tests may be repeated. If THC is positive at&#xD;
                  screening or check-in, a cannabis intoxication evaluation will be done by an&#xD;
                  investigator at check-in only; inclusion will be at the investigator's&#xD;
                  discretion, due to the slow release of THC from adipose tissue.&#xD;
&#xD;
          4. Smoking&#xD;
&#xD;
             a. Subject regularly smokes more than 10 cigarettes/day (or other nicotine-containing&#xD;
             products) or Subject has recently discontinued smoking (within the last 3 months)&#xD;
&#xD;
          5. Allergy/Intolerance&#xD;
&#xD;
             a. Subject has a history of allergy to d-MPH, to any component of the dosage form, or&#xD;
             any other allergy, which, in the opinion of an Investigator, contraindicates their&#xD;
             participation.&#xD;
&#xD;
          6. Clinical Studies&#xD;
&#xD;
               1. Participation in another investigational product study (inclusive of final&#xD;
                  post-study examination) or receipt of an investigational drug within the 30 days&#xD;
                  before screening day.&#xD;
&#xD;
               2. Previous participation in this study.&#xD;
&#xD;
          7. Personnel&#xD;
&#xD;
             a. An employee of the sponsor, study site, or members of their immediate family.&#xD;
&#xD;
          8. Blood&#xD;
&#xD;
               1. Subject has donated blood, plasma, or experienced significant blood loss (excess&#xD;
                  of 500 ml) within 3 months of screening and for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Brams, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince &amp; Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <results_first_submitted>March 12, 2021</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>bioavailability</keyword>
  <keyword>dexmethylphenidate</keyword>
  <keyword>BA study</keyword>
  <keyword>dMPH</keyword>
  <keyword>d-MPH</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04138498/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04138498/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at a single site from November 22, 2019 to March 06, 2020.</recruitment_details>
      <pre_assignment_details>Of 106 subjects who were screened, 45 (42.5%) were enrolled into the study and randomized to a sequence of treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 (ADBC)</title>
          <description>Subjects in sequence ADBC received study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 (BACD)</title>
          <description>Subjects in sequence BACD received study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3 (CBDA)</title>
          <description>Subjects in sequence CBDA received study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4 (DCAB)</title>
          <description>Subjects in sequence DCAB received study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1 (ADBC)</title>
          <description>Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2 (BACD)</title>
          <description>Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3 (CBDA)</title>
          <description>Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4 (DCAB)</title>
          <description>Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 6.25 mg Tablet: Experimental drug for comparative BA evaluation&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation&#xD;
Dexmethylphenidate 50 mg Tablet: Experimental drug for comparative BA evaluation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of ADHD</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>d-MPH Plasma concentration</description>
        <time_frame>Hours 0 to 28</time_frame>
        <population>PK Completer Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment B/A</title>
            <description>PK Comparison of 6.25 mg CTx-1301 (treatment B) to 5 mg Focalin XR (treatment A)</description>
          </group>
          <group group_id="O4">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O5">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O6">
            <title>Treatment D/C</title>
            <description>PK Comparison of 50 mg CTx-1301 (treatment D) to 40 mg Focalin XR (treatment C).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>d-MPH Plasma concentration</description>
          <population>PK Completer Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3138.41" lower_limit="2893.862" upper_limit="3403.633"/>
                    <measurement group_id="O2" value="2874.52" lower_limit="2646.813" upper_limit="3121.816"/>
                    <measurement group_id="O3" value="0.92" lower_limit="0.843" upper_limit="0.995"/>
                    <measurement group_id="O4" value="23884.13" lower_limit="22050.942" upper_limit="25869.722"/>
                    <measurement group_id="O5" value="24685.37" lower_limit="22774.231" upper_limit="26756.894"/>
                    <measurement group_id="O6" value="1.03" lower_limit="0.953" upper_limit="1.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-infinity)</title>
        <description>Area under the curve from time 0 extrapolated to infinite time</description>
        <time_frame>Hours 0 to 28</time_frame>
        <population>PK Completer Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment B/A</title>
            <description>PK Comparison of 6.25 mg CTx-1301 (treatment B) to 5 mg Focalin XR (treatment A)</description>
          </group>
          <group group_id="O4">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O5">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O6">
            <title>Treatment D/C</title>
            <description>PK Comparison of 50 mg CTx-1301 (treatment D) to 40 mg Focalin XR (treatment C).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-infinity)</title>
          <description>Area under the curve from time 0 extrapolated to infinite time</description>
          <population>PK Completer Population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24384.31" lower_limit="22579.167" upper_limit="26333.776"/>
                    <measurement group_id="O2" value="27661.46" lower_limit="25603.455" upper_limit="29884.885"/>
                    <measurement group_id="O3" value="1.13" lower_limit="1.090" upper_limit="1.181"/>
                    <measurement group_id="O4" value="203127.64" lower_limit="188123.507" upper_limit="219328.465"/>
                    <measurement group_id="O5" value="239317.53" lower_limit="221590.471" upper_limit="258462.729"/>
                    <measurement group_id="O6" value="1.18" lower_limit="1.133" upper_limit="1.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(Last)</title>
        <description>AUC from time 0 to the last measurable concentration</description>
        <time_frame>Hours 0 to 28</time_frame>
        <population>PK Completer Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment B/A</title>
            <description>PK Comparison of 6.25 mg CTx-1301 (treatment B) to 5 mg Focalin XR (treatment A)</description>
          </group>
          <group group_id="O4">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O5">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O6">
            <title>Treatment D/C</title>
            <description>PK Comparison of 50 mg CTx-1301 (treatment D) to 40 mg Focalin XR (treatment C).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(Last)</title>
          <description>AUC from time 0 to the last measurable concentration</description>
          <population>PK Completer Population</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22793.45" lower_limit="20666.366" upper_limit="25139.474"/>
                    <measurement group_id="O2" value="25540.99" lower_limit="23149.418" upper_limit="28179.632"/>
                    <measurement group_id="O3" value="1.12" lower_limit="1.075" upper_limit="1.169"/>
                    <measurement group_id="O4" value="190456.27" lower_limit="172736.598" upper_limit="209993.654"/>
                    <measurement group_id="O5" value="221949.48" lower_limit="201261.408" upper_limit="244764.129"/>
                    <measurement group_id="O6" value="1.17" lower_limit="1.118" upper_limit="1.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial AUCs</title>
        <description>AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16</description>
        <time_frame>Hours 0 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment B/A</title>
            <description>PK Comparison of 6.25 mg CTx-1301 (treatment B) to 5 mg Focalin XR (treatment A)</description>
          </group>
          <group group_id="O4">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O5">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O6">
            <title>Treatment D/C</title>
            <description>PK Comparison of 50 mg CTx-1301 (treatment D) to 40 mg Focalin XR (treatment C).</description>
          </group>
        </group_list>
        <measure>
          <title>Partial AUCs</title>
          <description>AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16</description>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4928.24" lower_limit="4520.066" upper_limit="5373.276"/>
                    <measurement group_id="O2" value="3943.21" lower_limit="3612.595" upper_limit="4304.075"/>
                    <measurement group_id="O3" value=".80" lower_limit="0.743" upper_limit="0.861"/>
                    <measurement group_id="O4" value="37963.37" lower_limit="34854.010" upper_limit="41350.112"/>
                    <measurement group_id="O5" value="32744.35" lower_limit="30044.791" upper_limit="35686.470"/>
                    <measurement group_id="O6" value=".86" lower_limit="0.803" upper_limit="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC3-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6939.76" lower_limit="6357.221" upper_limit="7575.675"/>
                    <measurement group_id="O2" value="6317.47" lower_limit="5778.203" upper_limit="6907.071"/>
                    <measurement group_id="O3" value="0.91" lower_limit="0.831" upper_limit="0.997"/>
                    <measurement group_id="O4" value="51204.34" lower_limit="46939.593" upper_limit="55856.559"/>
                    <measurement group_id="O5" value="51368.60" lower_limit="47085.223" upper_limit="56041.632"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.918" upper_limit="1.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC6-9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5644.67" lower_limit="5176.704" upper_limit="6154.948"/>
                    <measurement group_id="O2" value="5624.50" lower_limit="5149.945" upper_limit="6142.780"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.909" upper_limit="1.093"/>
                    <measurement group_id="O4" value="49159.01" lower_limit="45116.976" upper_limit="53563.164"/>
                    <measurement group_id="O5" value="53313.02" lower_limit="48889.077" upper_limit="58137.277"/>
                    <measurement group_id="O6" value="1.08" lower_limit="0.991" upper_limit="1.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2769.68" lower_limit="2498.675" upper_limit="3070.079"/>
                    <measurement group_id="O2" value="3638.05" lower_limit="3277.387" upper_limit="4038.399"/>
                    <measurement group_id="O3" value="1.31" lower_limit="1.198" upper_limit="1.440"/>
                    <measurement group_id="O4" value="25193.87" lower_limit="22743.535" upper_limit="27908.203"/>
                    <measurement group_id="O5" value="34316.26" lower_limit="30955.023" upper_limit="38042.466"/>
                    <measurement group_id="O6" value="1.36" lower_limit="1.245" upper_limit="1.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC12-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1643.22" lower_limit="1458.189" upper_limit="1851.741"/>
                    <measurement group_id="O2" value="3092.55" lower_limit="2739.223" upper_limit="3491.455"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.679" upper_limit="2.109"/>
                    <measurement group_id="O4" value="15739.33" lower_limit="13978.890" upper_limit="17721.462"/>
                    <measurement group_id="O5" value="26183.15" lower_limit="23231.791" upper_limit="29509.457"/>
                    <measurement group_id="O6" value="1.66" lower_limit="1.488" upper_limit="1.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>K</title>
        <description>Rate at which a drug is removed from the system</description>
        <time_frame>Hours 0 to 28</time_frame>
        <population>PK Completer Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
        </group_list>
        <measure>
          <title>K</title>
          <description>Rate at which a drug is removed from the system</description>
          <population>PK Completer Population</population>
          <units>(1/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.053"/>
                    <measurement group_id="O2" value="0.16" spread="0.040"/>
                    <measurement group_id="O3" value="0.17" spread="0.035"/>
                    <measurement group_id="O4" value="0.16" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life</title>
        <description>Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%</description>
        <time_frame>Hours 0 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life</title>
          <description>Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%</description>
          <units>hr*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="1.066"/>
                    <measurement group_id="O2" value="4.32" spread="1.866"/>
                    <measurement group_id="O3" value="4.05" spread="0.977"/>
                    <measurement group_id="O4" value="4.21" spread="1.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time (Hours) after administration of a drug when the maximum plasma concentration is reached</description>
        <time_frame>Hours 0 to 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time (Hours) after administration of a drug when the maximum plasma concentration is reached</description>
          <units>hr*pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="5.00" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="6.00" lower_limit="1.0" upper_limit="8.0"/>
                    <measurement group_id="O4" value="5.00" lower_limit="1.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tlag</title>
        <description>Delay (hours) between the time of dosing and time of appearance of concentration in the sampling</description>
        <time_frame>Hours 0 to 28</time_frame>
        <population>PK Completer Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
        </group_list>
        <measure>
          <title>Tlag</title>
          <description>Delay (hours) between the time of dosing and time of appearance of concentration in the sampling</description>
          <population>PK Completer Population</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-Emergent Adverse Events</title>
        <description>TEAEs will be measured from Day 0 to Day 10 (End of Study)</description>
        <time_frame>Day 0 to Day 10</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events</title>
          <description>TEAEs will be measured from Day 0 to Day 10 (End of Study)</description>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day -4 to Day 10</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Focalin XR 5 mg capsule&#xD;
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>CTx-1301 6.25 mg tablet&#xD;
Dexmethylphenidate 6.25 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>Focalin XR 40 mg capsule&#xD;
Dexmethylphenidate 40 Mg Oral Capsule, Extended Release: Reference listed drug (RLD) for comparative BA evaluation</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>CTx-1301 50 mg tablet&#xD;
Dexmethylphenidate 50 Mg Oral Tablet, Extended Release: Investigational Medication for comparative BA evaluation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pre-Existing Condition Improved</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure diastolic increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Change in Sustained Attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Frustration tolerance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution/PI shall not have the right to use the results pertaining to Institution's/PI's activities for their own instructional or research publication objectives, unless provided written permission by Sponsor. Publication must not disclose Confidential Information. Institution and PI shall submit in writing to Sponsor review of any Publication. Sponsor shall advise Institution of information which is Confidential Information or which may impair Sponsor's ability to obtain patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Operations and Regulatory Affairs</name_or_title>
      <organization>Cingulate Therapeutics</organization>
      <phone>913-942-2304</phone>
      <email>hmitzel@cingulatetherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

